No Data
No Data
Tectonic Therapeutic's Promising Clinical Developments: Buy Rating Affirmed by Tyler Van Buren
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Cuts Target Price to $101
Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $101
Tectonic Therapeutic Analyst Ratings
Piper Sandler Remains a Buy on Tectonic Therapeutic (TECX)
Tectonic Therapeutic: Undervalued Opportunity With Promising Catalysts and Strong Financial Position